Table 2 Characteristics of the cell product administered
Patient | Weight (Kg) | Dosage (× 106 per Kg) | Phase | Days of expansion | Viability (% of viable cells) | Karyotype | In vitro differentiation |
|---|---|---|---|---|---|---|---|
1 | 88 | 1.5 | 2° | 25 | 95 | 46, XY [17] | Yes |
2 | 82 | 1.5 | 1° | 18 | 91,8 | 46, XX [22] | Yes |
3 | 75.3 | 1.06 | 1° | 18 | 92 | No Metaphases | Yes |
4 | 75 | 1.33 | 1° | 26 | 97 | 46, XY [21] | Yes |
5 | 94 | 1.5 | 1° | 20 | 94 | 46, XY [20] | Yes |
6 | 68 | 1.5 | 2° | 26 | 97 | 46, XX [20] | Yes |
7 | 98 | 1.5 | 1° | 21 | 94 | 46, XY [20] | Yes |
8 | 74 | 1.5 | 1° | 20 | 95 | No Metaphases | No |
9 | 51 | 1.5 | 1° | 21 | 94 | 46, XX [15] | Yes |
10 | 84 | 1.5 | 2° | 26 | 100 | 46, XX [20] | Yes |
11 | 64 | 1.5 | 2° | 21 | 95 | 46, XX [21] | Yes |